13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001618205
Total reported value
$213.8M
$213.8M
59 檔
31.0%
As reported in its official Q1 2024 Form 13F filing, Birchview Capital, LP's tracked investment portfolio stood at $213.8M with 59 total positions.
During Q1 2024, Birchview Capital, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including BMY, NBIX, BIODESIX INC) accounted for 31.0% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 31.10% | -2.56% | +0.19% | |
| 2 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 8.68% | +0.10% | — | |
| 3 | ✓ | Biodesix Inc | Stock-Other | 6.22% | +0.65% | — | |
| 4 | ELUT | Elutia Inc | Stock-Other | 4.25% | -0.02% | — | |
| 5 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 3.77% | -0.15% | +4.16% | |
| 6 | OVV | Ovintiv Inc | Stock-Energy | 3.56% | -0.98% | — | |
| 7 | PRTA | Prothena Corporation plc | Stock-Other | 3.42% | -0.42% | — | |
| 8 | QDELUSD | Quidelortho CORP | Stock-Other | 2.55% | -0.04% | — | |
| 9 | SILKUSD | Silk Road Medical Inc | Stock-Other | 2.36% | — | — | |
| 10 | STOK | Stoke Therapeutics Inc | Stock-Other | 2.31% | -1.16% | — | |
| 11 | PHR | Phreesia Inc | Stock-Other | 2.24% | -0.07% | EXIT | |
| 12 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.06% | -0.38% | — | |
| 13 | MASI* | Masimo CORP | Stock-Other | 1.83% | — | — | |
| 14 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 1.76% | -0.13% | — | |
| 15 | HROW | Harrow Inc | Stock-Other | 1.62% | — | — | |
| 16 | DCGO | Docgo Inc | Stock-Other | 1.51% | — | +206.67% | |
| 17 | INBXUSD | Inhibrx Inc | Stock-Other | 1.38% | — | — | |
| 18 | ETRNUSD | Equitrans Midstream CORP | Stock-Other | 1.35% | — | — | |
| 19 | AXGN | Axogen Inc | Stock-Other | 1.14% | — | — | |
| 20 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.13% | -0.09% | — | |
| 21 | ALKS | Alkermes plc | Stock-Healthcare | 1.10% | +0.22% | — | |
| 22 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 1.03% | +1.25% | — | |
| 23 | ATEC | Alphatec Holdings Inc | Stock-Other | 0.99% | — | — | |
| 24 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.92% | — | — | |
| 25 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.86% | -0.32% | EXIT | |
| 26 | PXDEUR | Pioneer Natural Resources Co | Stock-Other | 0.81% | — | — | |
| 27 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.77% | +0.28% | — | |
| 28 | PGNY | Progyny Inc | Stock-Other | 0.68% | — | — | |
| 29 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.58% | -0.07% | — | |
| 30 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.57% | +0.07% | -60.00% | |
| 31 | CHRS | Coherus Oncology Inc | Stock-Other | 0.53% | — | +145.45% | |
| 32 | ARVN | Arvinas Inc | Stock-Other | 0.50% | — | — | |
| 33 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.48% | — | — | |
| 34 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.44% | -0.65% | EXIT | |
| 35 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.40% | — | — | |
| 36 | KROS | Keros Therapeutics Inc | Stock-Other | 0.38% | — | — | |
| 37 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.35% | -0.11% | — | |
| 38 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.35% | +0.01% | — | |
| 39 | ✓ | Stock-Other | 0.34% | — | — | ||
| 40 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.33% | +0.85% | — | |
| 41 | BHVN | Biohaven Ltd. | Stock-Other | 0.33% | — | — | |
| 42 | GTHXEUR | G1 Therapeutics Inc | Stock-Other | 0.28% | — | — | |
| 43 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 44 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.26% | — | — | |
| 45 | ✓ | Accelerate Diagnostics Inc | Stock-Other | 0.26% | — | +44.40% | |
| 46 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.26% | +0.11% | — | |
| 47 | CSTL | Castle Biosciences Inc | Stock-Other | 0.25% | -0.04% | +40.00% | |
| 48 | XNCR | Xencor Inc | Stock-Other | 0.22% | — | — | |
| 49 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.21% | -0.02% | EXIT | |
| 50 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.20% | — | — |
According to official SEC Form 13F filings, Birchview Capital, LP reported a total U.S. public equity portfolio value of $213.8M across 59 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q1 2024, Birchview Capital, LP's top holdings by market value included BMY (31.1%)、NBIX (8.7%)、BIODESIX INC (6.2%). The largest single position, BMY, represented 31.1% of total portfolio value.
In Q1 2024, Birchview Capital, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.